Checkpoint Surgical
Founded Year
2009Stage
Series C | AliveTotal Raised
$53.11MLast Raised
$16M | 2 yrs agoAbout Checkpoint Surgical
Checkpoint Surgical provides surgeons with neurodevices to preserve nerves and evaluate nerve and muscle excitability in surgical procedures for better patient outcomes. Checkpoint Surgical launched the CHECKPOINT Stimulator/Locator as its flagship product in a line of neuromuscular surgical devices.
Missing: Checkpoint Surgical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Checkpoint Surgical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Checkpoint Surgical
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Checkpoint Surgical in 1 CB Insights research brief, most recently on Mar 26, 2020.
Mar 26, 2020
40+ ‘Breakthrough’ Medical Device StartupsExpert Collections containing Checkpoint Surgical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Checkpoint Surgical is included in 2 Expert Collections, including Medical Devices.
Medical Devices
11,890 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,901 items
Checkpoint Surgical Patents
Checkpoint Surgical has filed 15 patents.
The 3 most popular patent topics include:
- Neurological disorders
- Neurotrauma
- Neurophysiology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/28/2021 | 7/5/2022 | Electrotherapy, Neuroprosthetics, Neurotechnology, Psychiatric diagnosis, Neurological disorders | Grant |
Application Date | 1/28/2021 |
|---|---|
Grant Date | 7/5/2022 |
Title | |
Related Topics | Electrotherapy, Neuroprosthetics, Neurotechnology, Psychiatric diagnosis, Neurological disorders |
Status | Grant |
Latest Checkpoint Surgical News
Oct 31, 2022
Checkpoint Surgical today announced the addition of CHECKPOINT GEMINI ™ to the company’s industry-leading line of intraoperative nerve stimulators. An addition to the company’s flagship CHECKPOINT Nerve Stimulator Portfolio , Checkpoint Gemini is designed to deliver more precise stimulation. “This expansion of Checkpoint Surgical’s stimulator portfolio ensures that we provide the surgeon with the optimal solution for clinical nerve procedures.,” said Derek Lewis, President, and CEO of Checkpoint Surgical. “Checkpoint Gemini complements our existing stimulators with a device optimized for precise nerve surgeries.” While CHECKPOINT GUARDIAN ™ offers the clinical versatility to locate nerves through dense tissue and assess motor nerve function, the new Checkpoint Gemini allows more precise direct nerve stimulation even at the fascicular level. Gemini has been designed to provide surgeons greater clarity to determine which fascicle within a nerve is responsible for which response. Checkpoint Gemini’s precision is made possible by the device’s innovative bipolar probe design, which focuses the energy delivered into a small area. This is in comparison to the monopolar probe of the Checkpoint Guardian, which delivers a broader field of stimulation. Checkpoint Gemini’s focused stimulation at 32Hz, provides a tetanic muscle response, even on fast-twitch muscle tissue such as that found in the face or pediatric anatomy. Read more about the new product here Post not marked as liked Follow us:
Checkpoint Surgical Frequently Asked Questions (FAQ)
When was Checkpoint Surgical founded?
Checkpoint Surgical was founded in 2009.
Where is Checkpoint Surgical's headquarters?
Checkpoint Surgical's headquarters is located at 22901 Millcreek Blvd, Beachwood.
What is Checkpoint Surgical's latest funding round?
Checkpoint Surgical's latest funding round is Series C.
How much did Checkpoint Surgical raise?
Checkpoint Surgical raised a total of $53.11M.
Who are the investors of Checkpoint Surgical?
Investors of Checkpoint Surgical include JumpStart, First Analysis, Mutual Capital Partners, RC Capital, Johnson & Johnson Innovation and 6 more.
Who are Checkpoint Surgical's competitors?
Competitors of Checkpoint Surgical include Noveome Biotherapeutics, Molmed, Sharklet Technologies, OxThera, Alta Devices and 11 more.
Compare Checkpoint Surgical to Competitors
RhinoCyte is a biotechnology company that has developed a method of isolating adult stem cells located in the olfactory regions of the mucosal lining of the human nasal passageway, which can be used in therapies for spinal cord injury, multiple sclerosis, ALS and Parkinson's Disease.
ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.
EnzymeRx is a private, clinical stage biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications in which hyperuricemia plays a causative role.
Timi3 Systems, Inc., a biotechnology company, develops a non-invasive transcutaneous ultrasound system for the treatment of patients experiencing an acute myocardial infarction or heart attack. The company specializes in the non-invasive delivery of thrombolytic drugs that hasten the dissolution of thrombus during a myocardial infarction. Timi3 Systems, Inc. was founded in 1999 and is based in Santa Clara, California.
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Cell Line Genetics aims to provide services and products to support research institutions, as well as biotechnology and pharmaceutical companies focused on embryonic stem cell and cancer research.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.